NEONC TECHNOLOGIES HOLDINGS, INC.

Cash redemption simplifies the capital structure with no common shares issued in the redemption CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash […] The post NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution appeared first on NeOnc Technologies Holdings, Inc..

CEO Amir Heshmatpour has purchased 111,000 shares for approximately $418,700 since the Company announced positive NEO100 Phase 2a results CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that […] The post NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results appeared first on NeOnc Technologies Holdings, Inc..

CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase […] The post NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors appeared first on NeOnc Technologies Holdings, Inc..

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% […] The post NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma appeared first on NeOnc Technologies Holdings, Inc..

CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2026, highlighted recent clinical and regulatory progress across its NEO100 and NEO212 programs, and […] The post NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout appeared first on NeOnc Technologies Holdings, Inc..

Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it […] The post NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma appeared first on NeOnc Technologies Holdings, Inc..

Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today […] The post NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors appeared first on NeOnc Technologies Holdings, Inc..

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212 CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written […] The post NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition appeared first on NeOnc Technologies Holdings, Inc..

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” […] The post NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone appeared first on NeOnc Technologies Holdings, Inc..

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 CALABASAS, Calif., […] The post NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development appeared first on NeOnc Technologies Holdings, Inc..